Group 1: Haier Biomedical - The overseas revenue distribution is as follows: Europe 40%, Africa 30%, Asia 20%, and America 10% [1] - The low-temperature storage market share is less than 10%, while smart medication and laboratory solutions show strong growth [1] - The company aims for a revenue growth target of 15%-30% through continuous implementation of co-creation strategies [1] - Domestic large project funnel growth is at 38%, with medical projects growing nearly 200% and pharmaceutical growth at 118% [1] - The company focuses on mergers and acquisitions to enhance value, targeting a double-digit capital return rate for subsidiaries in 2024 [1] Group 2: Tuojing Life - The company’s subsidiary, Hebei Tuojing, focuses on invasive fungal disease detection and has completed restructuring and integration [2] - The industry is significantly impacted by centralized procurement policies, with expectations for growth in self-immune testing, HPV screening, and thrombosis detection [2] - The company has made an asset impairment provision of approximately 13.44 million yuan, mainly due to bad debt losses and inventory adjustments [2] - The company seeks projects with clear clinical application value and technological innovation in the in vitro diagnostics field [2] Group 3: GuoDun Quantum - Quantum communication is transitioning from point applications to information security infrastructure construction, with operators investing in network construction [3] - China leads globally in quantum satellite communication, having launched multiple quantum satellites [3] - The company emphasizes independent research and development while collaborating with research institutions to incubate commercially viable products [3] - Quantum computing hardware sales cycles range from six months to a year, with service revenue being a smaller proportion [3] - The company is focused on building a complete ecosystem through cooperation, highlighting the importance of both hardware and software [3]

Group 1: Haier Biomedical - The overseas revenue distribution is 40% from Europe, 30% from Africa, 20% from Asia, and 10% from the Americas, with low-temperature storage market share below 10% [1] - Smart medication and blood technology each contribute 11% to revenue, while laboratory solutions account for 17%, with the former two being more profitable [1] - The company aims for a 15%-30% revenue growth through stock incentive plans, with significant growth in domestic large projects and a nearly 200% increase in medical projects [1] Group 2: Tuojing Life - The company focuses on invasive fungal disease detection, having completed restructuring and integration to enhance product development and clinical promotion [2] - The industry is significantly impacted by centralized procurement policies, with expectations for growth in self-immune testing, HPV screening, and thrombosis detection in the future [2] - The company has made a provision for asset impairment of approximately 13.44 million yuan, mainly due to bad debt losses and inventory adjustments [2] Group 3: Haitai New Light - Most products have been transferred to Thailand for mass production, with expectations to complete all product transfer approvals by Q3 [3] - Strong demand from overseas customers is anticipated, with continued growth in overseas shipments expected in the second half of the year [3] - The company has initiated cooperation with U.S. clients for the next-generation endoscope system, expanding from general surgery to head and neck surgery and orthopedics, which is expected to drive significant business growth [3]